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Edited by Masayuki MiyasakaAbstract Hereditary inclusion body myopathy (HIBM) is a
neuromuscular disorder, caused by mutations in UDP-N-acet-
ylglucosamine 2-epimerase/N-acetylmannosamine kinase, the
key enzyme of sialic acid biosynthesis. In Middle Eastern
patients a single homozygous mutation occurs, converting
methionine-712 to threonine. Recombinant expression of the
mutated enzyme revealed slightly reduced N-acetylmannosamine
kinase activity, in agreement with the localization of the
mutation within the kinase domain. B lymphoblastoid cell lines
derived from patients expressing the mutated enzyme also
display reduced UDP-N-acetylglucosamine 2-epimerase activity.
Nevertheless, no reduced cellular sialylation was found in those
cells by colorimetric assays and lectin analysis, indicating that
HIBM is not directly caused by an altered overall expression of
sialic acids.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Hereditary inclusion body myopathy (HIBM) is a neuro-
muscular disorder characterized by adult-onset, slowly pro-
gressive distal and proximal muscle weakness, and a typical* Corresponding author. Fax: +49-30-8445-1541.
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ManNAc kinase, N -acetylmannosamine kinase; UDP-GlcNAc 2-
epimerase, UDP-N -acetylglucosamine 2-epimerase
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doi:10.1016/j.febslet.2004.04.013muscle pathology including cytoplasmic rimmed vacuoles and
cytoplasmic or nuclear ﬁlamentous inclusions composed of
tubular ﬁlaments. Various hereditary forms with similar pre-
sentations have been described in diverse ethnic clusters. This
disease, occurring in various Middle Eastern population clus-
ters, is mostly common in the Jewish Persian community with
a prevalence of 1:1500 [1,2], and presents an unusual feature:
the sparing of the quadriceps. Recently, a single homozygous
missense mutation in all Persian and other Middle Eastern
Jewish HIBM patients in the gene encoding the enzyme UDP-
N -acetylglucosamine 2-epimerase/N -acetylmannosamine ki-
nase (UDP-GlcNAc 2-epimerase/ManNAc kinase; GNE) was
identiﬁed [3], conﬁrming the founder eﬀect hypothesis of this
disorder in Middle Eastern Jews. Moreover, diﬀerent missense
mutations in this same gene have been identiﬁed worldwide in
quadriceps sparing HIBM non-Jewish patients [3–5].
GNE is the key enzyme in the biosynthetic pathway of sialic
acid [6]. Sialic acids are the most abundant terminal mono-
saccharides on glycoproteins and glycolipids in eukaryotic
cells. They comprise a family of more than 50 naturally oc-
curring carboxylated amino sugars with a scaﬀold of nine
carbon atoms [7]. Sialic acids inﬂuence adhesion processes
which play an important role in many cellular functions, such
as cell migration, transformation of tissues, inﬂammation,
wound healing and metastasis [8,9]. The ﬁrst two steps of sialic
acid biosynthesis are catalyzed by one of the two distinct
functional domains of GNE. First, the UDP-GlcNAc 2-epi-
merase domain forms ManNAc from UDP-GlcNAc with si-
multaneous release of UDP. The ManNAc kinase domain then
phosphorylates ManNAc to create ManNAc 6-phosphate
[10,11]. In the following steps, sialic acid is formed by con-
densation of ManNAc-6-phosphate and phosphoenolpyruvate
and activated by CTP to form CMP–sialic acid. This nucleo-
tide sugar is used as a substrate of sialyltransferases in glyco-
conjugate biosynthesis [12].
HIBM patients worldwide display mutations in both do-
mains either in a homozygous form or, more commonly, in ablished by Elsevier B.V. All rights reserved.
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tation, occurring in Middle Eastern Jewish patients, is located
at the C-terminal end of the kinase domain. Although the role
of GNE has been thoroughly recognized as a key enzyme in
the biosynthetic pathway of sialic acid [6,13], the process by
which HIBM mutations in the enzyme lead to this muscle
disease is not yet understood. Here, we report the character-
ization of the recombinant M712T mutant GNE enzyme and
of HIBM patient-derived lymphoblastoid cells expressing the
mutated enzyme.2. Materials and methods
2.1. Materials
All chemicals and enzymes, if not otherwise indicated, were from
Sigma (Deisenhofen, Germany) or from Sigma, Israel.
2.2. Cloning of GNE cDNAs and generation of expression vectors
GNE cDNAs were generated from total RNA isolated from lym-
phoblastoid cell lines derived from a healthy individual and from an
HIBM patient carrying the M712T mutation in GNE by reverse
transcription (Superscript II reverse transcriptase; Gibco-BRL, Kar-
lsruhe, Germany) with random hexamer primers. PCR was then
performed to amplify GNE using primers BamX17F (CTATG-
GATCCTCGAGCCTCTCAAAACGAAACAAGC) and EcoK2251R
(GATTGAATTCGGTACCAGGAGCTCTGGAGAG- AAG). These
primers encompass GNE cDNA (Accession No. AJ238764) from nu-
cleotide #17 to nucleotide #2251 and include at their 50 ends sequential
restriction sites for BamHI–XhoI (New England Biolabs; Beverly,
USA), and for EcoRI–KpnI (New England Biolabs), respectively. PCR
products were cloned in either pcDNA3.1 (Invitrogen; Karlsruhe,
Germany) or pBluescript SK (Stratagene; La Jolla, USA) vectors.
2.3. Expression and puriﬁcation of GNE from insect cells
Generation of baculovirus and protein expression in insect cells was
done by the BAC-To-BAC system (Gibco-BRL). In brief, genes were
cloned from the cloning vectors into the expression vector pFAST-
BACHTa by XhoI and KpnI. The vectors were then transformed into
Escherichia coli DH10 BAC cells. Bacmid DNA was generated by
homologous recombination in the DH10 cells, isolated and Sf9 cells
were transfected with the DNA. After harvesting the ﬁrst virus, it was
ampliﬁed twice and the virus titer was determined after the last am-
pliﬁcation step. For protein expression, 2 106 cells/ml were infected
by the viruses with an MOI of 1 and incubated for 48 h. Cells were
harvested, washed once with PBS and used for protein preparation.
For protein puriﬁcation, cells were resuspended in 10 mM sodium
phosphate, pH 7.5, 1 mM EDTA, 1 mM dithiothreitol, 1 mM phen-
ylmethylsulfonyl ﬂuoride and lysed by 20 strokes through a syringe
with a 26 gauge needle. The lysate was centrifuged at 20 000 g for 20
min and the supernatant applied to a Ni–NTA column (0.5 ml; Qiagen;
Hilden, Germany). The column was washed with 5 ml of 10 mM
NaH2PO4 300 mM NaCl, 0.1 mM EDTA, 1 mM dithiothreitol, 20
mM imidazole (pH 8.0) and proteins were eluted in 2 ml of 10 mM
NaH2PO4, 300 mM NaCl, 0.1 mM EDTA, 1 mM dithiothreitol, and
100 mM imidazole (pH 8.0). Fractions containing protein were applied
to a PD-10 gel ﬁltration column (Amersham; Freiburg, Germany) and
eluted with 10 mM NaH2PO4 (pH 7.5), 100 mM NaCl, 1 mM EDTA,
1 mM dithiothreitol and 0.1 mM UDP. Fractions were checked for
protein concentration by the Coomassie protein assay kit (BioRad;
M€unchen, Germany) and for purity by SDS–PAGE using a Mini-
Protean II system (BioRad).
2.4. Enzyme assays
The assay used to determine the epimerase activity of a recombinant
GNE contained 45 mM Na2HPO4, pH 7.5, 10 mM MgCl2, 1 mM
UDP-GlcNAc and 0.2–1 lg of protein in a ﬁnal volume of 200 ll. The
reaction was performed at 37 C for 30 min and stopped by heating at
100 C for 1 min. ManNAc produced in this reaction was detected by
the Morgan–Elson method [14]. In brief, 150 ll of sample was mixed
with 30 ll of 0.8 M H2BO3, pH 9.1, and boiled for 3 min. Then, 800 ll
of DMAB solution (1% (w/v) 4-dimethylamino benzaldehyde in aceticacid/1.25% 10 N HCl) was added and incubated at 37 C for 30 min.
The absorbance was read at 578 nm.
The assay used to determine the kinase assay of recombinant GNE
contained 60 mM Tris/HCl, pH 8.1, 10 mM MgCl2, 5 mM ManNAc,
10 mM ATP, 0.2 mM NADH, 2 mM phosphoenolpyruvate, 2 U py-
ruvate kinase, 2 U lactate dehydrogenase and 0.1–0.5 lg of protein in a
ﬁnal volume of 200 ll. The reaction was performed for 20 min at 37 C
and stopped by addition of 800 ll of 10 mM EDTA. The decrease of
NADH was monitored at 340 nm.
UDP-GlcNAc 2-epimerase activity in lymphoblastoid cells was de-
termined as previously described [10]. Cytosolic supernatant was pre-
pared by using the procedure described above for insect cells. Assays
were performed in a ﬁnal volume of 200 ll, containing 35 mM sodium
phosphate, pH 7.5, 4 mMMgCl2, 0.5 mM UDP-GlcNAc, 50 nCi [
14C]
UDP-GlcNAc and 300 lg of cytosolic protein. Incubations were car-
ried out at 37 C for 3 h and stopped by addition of 300 ll ethanol.
Radiolabelled substrates were separated by descending paper chro-
matography and quantiﬁed by liquid scintillation analysis. All speciﬁc
activities were given as U/mg of protein. One unit is deﬁned as the
formation of 1 lmol product per minute.
The overall reaction of recombinant GNE was determined by a
similar assay. A ﬁnal volume of 200 ll contained 35 mM sodium
phosphate, pH 7.5, 4 mM MgCl2, 0.5 mM UDP-GlcNAc, 12.5
nCi[14C] UDP-GlcNAc, 10 mM ATP and 0.2 lg of puriﬁed protein.
Incubations were carried out at 37 C for 30 min and stopped by ad-
dition of 300 ll ethanol. Radiolabelled substrates were separated by
descending paper chromatography and quantiﬁed by liquid scintilla-
tion analysis. The Rf values were 0.08 for UDP-GlcNAc, 0.55 for
ManNAc and 0.17 for ManNAc-6-phosphate.
2.5. Cell cultures
Lymphoblastoid cells were grown in RPMI medium supplemented
with 10% fetal calf serum (Biological Industries, Beit Haemek, Israel).
For bound sialic acid determination, sialic acid uptake was avoided by
growing the cells in serum-free medium (DCCM, Biological Industries)
for 4–5 days prior to performing the assay.
2.6. Sialic acid quantiﬁcation
Membrane-bound sialic acid was quantiﬁed by the periodate/resor-
cinol method [15]. In brief, lysates from 20 106 cells obtained after
lysis as described above were oxidized in 250 ll with 5 ll of 0.4 M
periodic acid at 37 C for 90 min, followed by 15 min boiling in 500 ll
of 6% resorcinol/2.5 mM CuSO4/44% HCl. After cooling for a few
minutes, 500 ll tert-butyl alcohol was added, the samples were vor-
texed and centrifuged for 5 min to precipitate cell debris. Immediately
after spinning, the supernatants were poured into OD cuvettes and
read at 630 nm. Sialic acid concentrations were calculated by com-
parison with a standard curve (usually in a range of 0–250 lM sialic
acid) and expressed in nanomoles per mg cytosolic protein.
2.7. FACS analysis
106 cells were incubated for 45 min directly with 1 lg of either FITC-
Maackia amurensis agglutinin (MAA) (EY Laboratories, CA, USA),
FITC-Sambucus nigra agglutinin (SNA) (EY Laboratories), or with
biotin-TML (Calbiochem, CA, USA) followed by an additional 45 min
incubation with 1 lg FITC–streptavidin (Sigma). Two washes with 1
ml PBS each were performed between all steps. Cell ﬂuorescence was
analyzed in a Becton–Dickinson FACS apparatus.3. Results and discussion
3.1. Functional expression and characterization of human GNE
and the M712T mutant in insect (Sf9) cells
The expression of GNE in most human tissues or cell lines is
low making it very diﬃcult to isolate and purify suﬃcient
amounts of this enzyme for biochemical characterization from
these sources. To avoid this limitation, we cloned the cDNA of
wild-type and mutated GNE from patient-derived lympho-
blastoid cell lines and expressed it in insect (Sf9) cells by the
baculovirus expression system. This system is well suited for
GNE expression, as previously shown for the rat enzyme [11].
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fuses the resulting protein with an N-terminal 6His-tag.
Baculoviruses generated from these vectors were used to infect
Sf9 cells, which then produced recombinant GNE. After cell
lysis, proteins were puriﬁed from the cytosol by Ni–NTA
chromatography. Imidazole used in this step aﬀects GNE
stability requiring that it be removed by chromatography on
PD-10 gel ﬁltration columns immediately after Ni–NTA aga-
rose chromatography. GNE preparations obtained after this
step were active for several days at 4 C. SDS–PAGE analysis
showed the presence of 80 kDa bands for the wild-type enzyme
and the M712T mutant, and purity of the samples of more
than 90% (data not shown).
The epimerase and kinase enzyme activities of the two forms
of recombinant GNE were determined. First, both enzymes
showed similar UDP-GlcNAc 2-epimerase activities (Fig. 1A).
Furthermore, UDP-GlcNAc 2-epimerase activity of the wild-
type as well as the M712T mutant enzymes was completely
inhibited by 100 lM CMP-Neu5Ac, the feed-back inhibitor of0
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Fig. 1. Enzyme activities of recombinant wild-type and M712T GNE.
(A) Speciﬁc enzyme activities. Enzymes were expressed in Sf9 cells,
puriﬁed by Ni–NTA-chromatography and assayed for enzyme activi-
ties as described under Sections 2.3 and 2.4. Values are means S.D.
of ﬁve independent enzyme preparations. (B) Overall reaction of GNE.
Puriﬁed enzymes were incubated with radiolabelled UDP-GlcNAc in
the presence of unlabelled ATP as described under Section 2.4. Rela-
tive amounts of ManNAc and ManNAc-6-phosphate were determined
by paper chromatography. Values are meansS.D. of three inde-
pendent experiments.this enzyme activity (data not shown). The ManNAc kinase
activity of the M712T mutant was reduced by about 30%
compared to the wild-type enzyme (Fig. 1A). These results are
consistent with localization of the M712T mutation in the ki-
nase domain of GNE. The oligomerization was also analyzed
for both enzymes. Both wild-type and mutated GNE assemble
as homohexamers of six subunits (data not shown). These re-
sults indicate, that the M712T mutation causes only subtle
eﬀects in vitro, speciﬁcally aﬀecting the kinase domain of the
recombinant enzyme.
In the wild-type enzyme, the speciﬁc activity of UDP-Glc-
NAc 2-epimerase is nearly 2-fold lower than the speciﬁc ac-
tivity of ManNAc kinase (Fig. 1A). Therefore, the epimerase
activity might be rate-limiting for the overall reaction of the
bifunctional enzyme. We therefore developed an assay check-
ing the two-step conversion of UDP-GlcNAc to ManNAc 6-
phosphate. Wild-type and mutated GNE, incubated in the
presence of radiolabelled UDP-GlcNAc and non-labelled
ATP, were analyzed for production of ManNAc and Man-
NAc-6-phosphate. Under these assay conditions, wild-type
GNE immediately converted more than 80% of the ManNAc
generated by UDP-GlcNAc 2-epimerase to ManNAc-6-phos-
phate (Fig. 1B). This result conﬁrmed that the ManNAc kinase
domain of GNE has a higher metabolic rate than UDP-Glc-
NAc 2-epimerase. The same result was found for the M712T
mutant GNE. So at least in this in vitro assay, the mutation
does not result in a signiﬁcant change of the production of
ManNAc 6-phosphate by the enzyme.
The localization of the M712T mutation within the tertiary
structure GNE is currently unknown because the crystal
structure of this enzyme is not yet available. Sequence simi-
larities with other sugar kinases reveal a conserved region
between amino acids 410 and 684 [11], most likely representing
the core of the kinase domain. We therefore speculate that
M712 is located outside of the core region that determines
kinase activity, thereby accounting for the minor eﬀects of this
mutation on enzyme activities.
3.2. Characterization of GNE activities in patient-derived
lymphoblastoid cell lines
In order to characterize the M712T mutant in a cellular
system, we used B lymphoblastoid cell lines derived from
HIBM patients, healthy controls and heterozygous carriers of
the mutation. For each group at least ﬁve individual cell lines
were investigated for UDP-GlcNAc 2-epimerase activity
(Fig. 2). The mean activities were 0.24 0.03 mU/mg for
control cells, 0.21 0.04 mU/mg for cells of heterozygous
carriers and 0.15 0.02 mU/mg for cells from patients with
clinical symptoms of HIBM. Whereas no signiﬁcant reduction
was found for cells from heterozygous carriers compared to
normal cells, UDP-GlcNAc 2-epimerase activity was reduced
by about 35% in patient cells. This result is in contrast to the
ﬁndings for the recombinant GNE proteins produced in insect
cells, which displayed no diﬀerence in UDP-GlcNAc 2-epi-
merase activity. In order to exclude the possibility that the
decrease in epimerase activity results from alterations in the
GNE expression level, cells were checked by Western blot
analysis, and no expression diﬀerences were found between cell
lines derived from HIBM patients and their healthy controls
(data not shown). It was not possible to detect the kinase ac-
tivity speciﬁcally resulting from ManNAc kinase in the cell
lines we investigated from human patients because of the low
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Fig. 2. UDP-GlcNAc 2-epimerase activity in B lymphoblastoid cell
lines. Enzyme activities were determined in the cytosol of cell lines
from healthy control individuals (normals), heterozygous carriers of
the M712T mutation (heterozygous), and HIBM patients (aﬀected) as
described under Section 2.4. Values are meansS.D. of three inde-
pendent experiments.
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kinases other than GNE in the lymphoblastoid cells. In par-
ticular, GlcNAc kinase has a high intrinsic ManNAc kinase
activity [16], which would be capable of masking any kinase
deﬁciencies of GNE in cells. Therefore, the question is still
open whether cellular GNE also displays a 30% reduction of
ManNAc kinase activity for the M712T mutation, as found for
the mutated recombinant enzyme. Because speciﬁc inhibitors
of GlcNAc kinase are not available to date, another potential
method to measure ManNAc kinase activities may take ad-
vantage of the high molecular mass of hexameric GNE. The
protein may be separated from other sugar kinases by gel ﬁl-
tration prior to enzyme assays. Nevertheless, for cells with very
low expression of GNE, as the lymphoblastoid cells used in
this study, this method is not promising.
Another factor that makes the analysis of the exact cellular
eﬀects of GNE mutations diﬃcult is the ability of this enzyme
to be regulated by various mechanisms. For example, it is
known that phosphorylation of GNE by protein kinase C in-
creases UDP-GlcNAc 2 epimerase activity [17]. Also the GNE
protein can be modiﬁed by the addition of O-linked N -acet-
ylglucosamine residues (R. Horstkorte, unpublished observa-
tion). It is possible that the M712T mutation impairs such
cellular mechanisms and thus destabilizes the entire GNE
molecule, thereby indirectly aﬀecting both enzymatic activities.
Ultimately, an understanding of both aﬀected and unaﬀected
cells will be required to fully understand the cellular basis ofTable 1
Overall sialic acid detection in lymphoblastoid cell lines by the periodate/res
Cells Membrane-bound sialic acids TML
nmol/mg protein Mean ﬂuorescence intensity
Normal 26 6 (5) 18 10 (5)
Aﬀected 29 9 (5) 10 3 (5)
Values are meansS.D. of the data of the indicated number of cell lines.HIBM. Further studies, therefore, are underway to reveal if
alterations of UDP-GlcNAc 2-epimerase activity are present in
other cell types expressing the mutated enzyme. Of particular
interest are myocytes or neuronal cells implicated in the muscle
disorders found in HIBM.
3.3. Characterization of sialylation in patient-derived
lymphoblastoid cell lines
Since we measured reduced UDP-GlcNAc 2-epimerase ac-
tivity in all cell lines of HIBM patients, together with the re-
duced ManNAc kinase activity of the recombinant enzyme, we
analyzed sialic acid expression of all cell lines. Membrane-
bound sialic acids (including plasma membrane, membranes of
the Golgi apparatus and lysosomal membranes) were quanti-
ﬁed by the colorimetric periodate/resorcinol assay (Table 1).
No signiﬁcant diﬀerence was found between cells of healthy
individuals and cells homozygously expressing the M712T
mutant GNE. It is well known, that cells are able to take up
sialic acids or its metabolic precursors from the culture me-
dium and convert them to glycoconjugate-bound sialic acids
[18]. Because these sugars are especially abundant in the sup-
plemented serum, we therefore changed culture conditions and
used serum-free medium with a very low content of sialic acids.
The question was, whether these conditions may reveal an
hyposialylated phenotype. No diﬀerence, however, was found
in the overall membrane-bound sialic acids contents of control
and patient-derived cells even when this sialic acid depleted
media were used (data not shown).
To verify these results, cell surface expression of sialic acids
was analyzed using several sialic acid speciﬁc lectins. Tri-
trichomonas mobilensis lectin (TML) binds to sialic acid in
a2,3-, a2,6- and a2,8-linkages. Furthermore, its aﬃnity is in-
ﬂuenced by modiﬁcations in sialic acids, such as acetylation or
the N -glycolyl modiﬁcation [19]. No signiﬁcant diﬀerence in
TML binding was found between HIBM and healthy control
cells when analyzed by FACS (Table 1; Fig. 3). These results
conﬁrm data from the periodate/resorcinol assay that showed
unchanged overall sialylation and further indicated that there
is no obvious altered expression of the diﬀerently linked types
of sialic acid. Next we used two linkage-speciﬁc lectins, MAA
for a2,3-linked sialic acids and SNA for a2,6-linked sialic
acids, in order to investigate more subtle changes in sialic acid
expression. Here again, the analysis of the cells by FACS with
these lectins showed no signiﬁcant diﬀerences between patient-
derived and control cells (Table 1; Fig. 3). We then used MAA
in lectin blot analysis of membrane glycoproteins. No reduc-
tion in MAA speciﬁc sialylation was found in the proteins of
patient-derived cells in this experiment either (data not
shown).
Our data do not reveal any inﬂuence of the M712T muta-
tion on the expression of sialic acids on the lymphoblastoid
cell lines. Obviously, the cells are able to compensate for the
reduced enzymatic activities of GNE. Whereas a loss oforcinol assay and by FACS analysis
MAA SNA
Mean ﬂuorescence intensity Mean ﬂuorescence intensity
53 21 (4) 179 71 (5)
50 14 (9) 155 60 (6)
Fig. 3. Cell surface sialylation of B lymphoblastoid cell lines. Sialylation was FACS-analyzed by the sialic acid speciﬁc lectins TML, MAA and SNA
as described under Section 2.7. U, Untreated lymphoblastoid cells; H, lymphoblastoid cells from a healthy individual; A, lymphoblastoid cells from
an HIBM aﬀected patient.
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GlcNAc kinase [16], there is no alternative known for UDP-
GlcNAc 2-epimerase. Accordingly, the 35% reduction of ep-
imerase activity found in M712T cells seems to be within the
range of acceptable changes to enzyme activity needed to
maintain intact sialic acid metabolism. This ﬁnding may also
be due to the fact that lymphocytes required relatively low
levels of sialic acids in contrast to, for example, hepatocytes,
which synthesize large amounts of sialylated serum glyco-
proteins. On the other hand no liver failure has been reported
in HIBM patients, indicating that reduced activities of GNE
do not lead to reduced sialylation in most tissues. It is likely
that the range of ‘‘acceptable changes’’ is variable in diﬀerent
tissues, with eﬀects being more likely to be felt in cells with
relatively low levels of GNE expression, such as muscle cells,
but high requirements for sialic acid. In a very recent study,
Noguchi et al. [20] showed that muscle cells from Japanese
HIBM patients, carrying other mutations than M712T, may
have slightly reduced sialic acid content and hyposialylation
in primary cultured myoﬁbers. It is also possible that a slight
reduction of sialylation occurs in a speciﬁc protein which
may not be relevant for lymphocyte metabolism, but that
could be essential in muscle physiology, thus leading to the
HIBM phenotype. Although in more than 120 patients with
the M712T mutation no other consistent disorder was asso-
ciated with the GNE defect, additionally it may be possible
that GNE or one of the various enzymes acting downstream
is involved in additional pathways, not related to sialic acid
biosynthesis. The ﬁndings in this study indicate that the
mechanism of HIBM cannot be explained easily through the
well characterized sialic acid pathway in cellular metabo-
lism and the role of GNE in this disease remains still enig-
matic. Further studies on muscle cells will therefore be
essential to give more insights into the pathophysiology of
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